Literature DB >> 22710961

Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases.

Andrea L Wiens1, Liang Cheng, Elizabeth C Bertsch, Karen A Johnson, Shaobo Zhang, Eyas M Hattab.   

Abstract

It is well established that the combined del(1)(p36) and del(19)(q13) is a positive prognostic molecular event in oligodendroglial tumors. However, very little is known about the frequency or impact of polysomy status for chromosomes 1/19. We examined 84consecutive pure oligodendrogliomas (68 World Health Organization [WHO] grade II and 16 WHO grade III) and analyzed them for del(1)(p36) and del(19)(q13) by fluorescent in situ hybridization. Polysomy status was recorded with accompanying deletion status, WHO grade, recurrence-free survival, and overall survival. Codeletion of 1p/19q was detected in 48% of cases and correlated with superior patient survival (p < 0.01), as expected. Of 84 cases, 36 (43%) showed polysomy of chromosome 1, 30 (36%) demonstrated polysomy of chromosome 19, and 28 (33%) had copolysomies of chromosomes 1/19. The presence of polysomy of either/or both chromosomes, regardless of deletion status, correlated with younger patient age at initial diagnosis (p < 0.01). Combined polysomy was associated with higher histologic tumor grade (p = 0.04) and conferred poor survival likelihood (p = 0.03). We conclude that polysomy of 1 and/or 19 is a relatively frequent occurrence in oligodendrogliomas and usually confers an unfavorable outcome.

Entities:  

Mesh:

Year:  2012        PMID: 22710961     DOI: 10.1097/NEN.0b013e31825b5f7a

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  16 in total

1.  Renal cell carcinoma with angioleiomyoma-like stroma: clinicopathological, immunohistochemical, and molecular features supporting classification as a distinct entity.

Authors:  Sean R Williamson; Liang Cheng; John N Eble; Lawrence D True; Nilesh S Gupta; Mingsheng Wang; Shaobo Zhang; David J Grignon
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

2.  Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.

Authors:  Saeko Hayashi; Yohei Kitamura; Yuichi Hirose; Kazunari Yoshida; Hikaru Sasaki
Journal:  J Neurooncol       Date:  2016-12-26       Impact factor: 4.130

3.  How molecular testing can help (and hurt) in the workup of gliomas.

Authors:  Kenneth Clark; Zoya Voronovich; Craig Horbinski
Journal:  Am J Clin Pathol       Date:  2013-03       Impact factor: 2.493

4.  High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

Authors:  Eril J Kouba; John N Eble; Novae Simper; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lisha Wang; Guido Martignoni; Sean R Williamson; Matteo Brunelli; Claudio Luchini; Anna Calió; Liang Cheng
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

5.  Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.

Authors:  Xiaohui Ren; Haihui Jiang; Xiangli Cui; Yong Cui; Jun Ma; Zhongli Jiang; Dali Sui; Song Lin
Journal:  Neuro Oncol       Date:  2013-07-16       Impact factor: 12.300

6.  Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors.

Authors:  Haihui Jiang; Xiaohui Ren; Zhe Zhang; Wei Zeng; Junmei Wang; Song Lin
Journal:  J Neurooncol       Date:  2014-07-10       Impact factor: 4.130

7.  Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.

Authors:  Marc C Chamberlain; Donald Born
Journal:  J Neurooncol       Date:  2015-09-04       Impact factor: 4.130

8.  Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors.

Authors:  Hui Chen; Cheddhi Thomas; Felipe Andres Munoz; Sanda Alexandrescu; Craig M Horbinski; Adriana Olar; Declan McGuone; Sandra Camelo-Piragua; Lu Wang; Elena Pentsova; Joanna Phillips; Kenneth Aldape; Wen Chen; A John Iafrate; Andrew S Chi; David Zagzag; John G Golfinos; Dimitris G Placantonakis; Marc Rosenblum; Pamela Ohman-Strickland; Meera Hameed; Matija Snuderl
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 13.029

Review 9.  Oligodendroglioma: pathology, molecular mechanisms and markers.

Authors:  Pieter Wesseling; Martin van den Bent; Arie Perry
Journal:  Acta Neuropathol       Date:  2015-05-06       Impact factor: 17.088

10.  Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.

Authors:  Céline Duval; Marie de Tayrac; Karine Michaud; Florian Cabillic; Claudie Paquet; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.